Literature DB >> 23877665

Limiting "evergreening" for a better balance of drug innovation incentives.

Matthew B Stanbrook.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23877665      PMCID: PMC3735737          DOI: 10.1503/cmaj.130992

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Manitoba kills cardiac care unit, consolidates services at single site.

Authors:  Barbara Sibbald
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

2.  Evergreening: a common practice to protect new drugs.

Authors:  Kate S Gaudry
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

3.  Drug patents: the evergreening problem.

Authors:  Roger Collier
Journal:  CMAJ       Date:  2013-04-29       Impact factor: 8.262

4.  Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?

Authors:  Joel Lexchin
Journal:  BMC Health Serv Res       Date:  2011-03-24       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.